BACKGROUND: Male breast cancer accounts for less than 1% of all breast cancers, yet males have a worse prognosis than females with breast cancer. METHODS: Using the 1988-2003 Surveillance, Epidemiology, and End Results Program data, we conducted a retrospective, population-based cohort study to investigate stage-specific differences in breast cancer-specific and all-cause mortality between males and females. We calculated adjusted hazard ratios (aHR) and 95% confidence intervals (CI) using Cox regression models to compare breast cancer-specific and all-cause mortality by stage between males and females, controlling for potential confounding variables. RESULTS: There were 246,059 patients with a first, single, primary breast cancer [1,541 (0.6%) male; 244,518 (99.4%) female]. Compared with females, males were more likely to be older, Black, married, diagnosed at more advanced stages, and treated with mastectomy (each P < 0.001). Males also were more likely to have lower grade and estrogen/progesterone receptor-positive tumors (each P < 0.001). After controlling for confounders, males were more likely to die from their breast cancer when compared with females, only if diagnosed with stage I disease (aHR 1.72, CI 1.15-2.61). For all-cause mortality, males were more likely than females to die at each stage of disease except stage IV. CONCLUSIONS: Although all-cause mortality was higher for men than women at all stages of nonmetastatic breast cancer, higher male breast cancer-specific mortality was attributed to poorer survival in stage I disease. However, this statistical difference is unlikely to be clinically relevant and attributable to in-stage migration.
BACKGROUND:Male breast cancer accounts for less than 1% of all breast cancers, yet males have a worse prognosis than females with breast cancer. METHODS: Using the 1988-2003 Surveillance, Epidemiology, and End Results Program data, we conducted a retrospective, population-based cohort study to investigate stage-specific differences in breast cancer-specific and all-cause mortality between males and females. We calculated adjusted hazard ratios (aHR) and 95% confidence intervals (CI) using Cox regression models to compare breast cancer-specific and all-cause mortality by stage between males and females, controlling for potential confounding variables. RESULTS: There were 246,059 patients with a first, single, primary breast cancer [1,541 (0.6%) male; 244,518 (99.4%) female]. Compared with females, males were more likely to be older, Black, married, diagnosed at more advanced stages, and treated with mastectomy (each P < 0.001). Males also were more likely to have lower grade and estrogen/progesterone receptor-positive tumors (each P < 0.001). After controlling for confounders, males were more likely to die from their breast cancer when compared with females, only if diagnosed with stage I disease (aHR 1.72, CI 1.15-2.61). For all-cause mortality, males were more likely than females to die at each stage of disease except stage IV. CONCLUSIONS: Although all-cause mortality was higher for men than women at all stages of nonmetastatic breast cancer, higher male breast cancer-specific mortality was attributed to poorer survival in stage I disease. However, this statistical difference is unlikely to be clinically relevant and attributable to in-stage migration.
Authors: Mahmoud B El-Tamer; Ian K Komenaka; Andrea Troxel; Huiling Li; Kathie-Ann Joseph; Beth-Ann Ditkoff; Freya R Schnabel; David W Kinne Journal: Arch Surg Date: 2004-10
Authors: B Cutuli; M Lacroze; J M Dilhuydy; M Velten; B De Lafontan; C Marchal; M Resbeut; Y Graic; F Campana; V Moncho-Bernier Journal: Eur J Cancer Date: 1995-11 Impact factor: 9.162
Authors: Jessica Wang-Rodriguez; Keith Cross; Scott Gallagher; Marcia Djahanban; Janet M Armstrong; Noel Wiedner; David H Shapiro Journal: Mod Pathol Date: 2002-08 Impact factor: 7.842
Authors: Kelsey L Corrigan; Walker Mainwaring; Austin B Miller; Timothy A Lin; Amit Jethanandani; Andres F Espinoza; Matt Piotrowski; C David Fuller; Michael C Stauder; Simona F Shaitelman; George H Perkins; Wendy A Woodward; Sharon H Giordano; Benjamin D Smith; Ethan B Ludmir Journal: Oncologist Date: 2020-04-28
Authors: Icro Meattini; L Livi; D Franceschini; C Saieva; V Scotti; D Casella; V Criscenti; I Zanna; F Meacci; E Gerlain; B Agresti; M Mangoni; F Paiar; G Simontacchi; D Greto; J Nori; S Bianchi; L Cataliotti; G Biti Journal: Radiol Med Date: 2012-08-08 Impact factor: 3.469
Authors: Suleiman Alfred Massarweh; George W Sledge; Dave P Miller; Debbie McCullough; Valentina I Petkov; Steven Shak Journal: J Clin Oncol Date: 2018-03-27 Impact factor: 44.544
Authors: Paulo Franscisco Mascarenhas Bender; Letícia Lima de Oliveira; Célia Regina Costa; Suzana Sales de Aguiar; Anke Bergmann; Luiz Claudio Santos Thuler Journal: J Cancer Res Clin Oncol Date: 2016-12-08 Impact factor: 4.553
Authors: Kenneth L Kehl; Chan Shen; Jennifer K Litton; Banu Arun; Sharon H Giordano Journal: Breast Cancer Res Treat Date: 2015-12-26 Impact factor: 4.872